Clinical trials: Cyclic Vomiting Syndrome
Cyclic Vomiting Syndrome
Analysis of Q10 Coenzyme Efficacy for Long-term Treatment of Cyclic Vomiting Syndrome in Children
The main purpose of this study is the comparison of frequency of vomiting episodes (number of episodes per year) observed during the year after the begin of Q10 coenzyme treatment to frequency observed during the year before the…
- Trial name
- COENZYME (NCT03295760)
- Testing
- Q10 Coenzyme
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Central Hospital, Nancy, France
Cyclic Vomiting Syndrome
Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis
The purpose of this study is to compare two commonly used agents for the treatment of cyclic vomiting to see if one agent is inferior to the other in time to improvement in symptoms, need for repeat or rescue medications…
- Trial name
- NCT05065567
- Testing
- Droperidol, Haloperidol, Ondansetron 8mg
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Corewell Health South
Functional Gastrointestinal Disorders (FGIDs), Cyclic Vomiting Syndrome
Autonomic Reactivity and Personalized Neurostimulation
Disorders of gut-brain interaction (DGBI) affect up to 25% of U.S. children. Patients often suffer from disabling, multisystem comorbidities that suggest a common root (sleep disturbances, fatigue, anxiety, etc).
- Conditions
- Functional Gastrointestinal Disorders (FGIDs), Cyclic Vomiting Syndrome, Functional Dyspepsia, Dysautonomia
- Trial name
- NCT06863207
- Testing
- Percutaneous electrical nerve field stimulation, Hypnotherapy
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Cannabis Use Disorder
Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)
Cannabis Hyperemesis Syndrome (CHS) has become a well-documented syndrome since 2004 and is expected to increase in prevalence with continuing liberalization of marijuana and recognition of the disease.
- Trial name
- HaVOC (NCT03056482)
- Testing
- Ondansetron 8mg, Haloperidol 0.05mg/kg, Haloperidol 0.1mg/kg
- Where
- 3 sites in Canada
- Volunteers
- 33 people
- Sponsor
- Dr. Marco L.A. Sivilotti
Motility Disorder, Gastroparesis
Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls
This is an analytical validation observational cohort study is designed to provide evidence of: safety and reliability of Body Surface Gastric Mapping using the Gastric Alimetry System (GAS), normal reference values, and…
- Conditions
- Motility Disorder, Gastroparesis, Functional Dyspepsia, Cyclical Vomiting
- Trial name
- NCT05812339
- Testing
- Gastric Alimetry System
- Where
- Canada
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Calgary